论文部分内容阅读
肾癌组织病理学分类复杂多样,但从临床药物治疗上分为透明细胞癌和非透明细胞癌两大类型。在我国目前对于转移性肾癌患者,药物治疗推荐分子靶向药物——索拉非尼为一线方案,其他分子靶向药物的推荐有待于中国的临床试验结果;细胞因子IFN-α或IL-2治疗对透明细胞癌类型肾癌也为一线推荐方案,而化疗可作为转移性非透明细胞类型肾癌的选择方案。伴有肾癌骨转移患者,推荐应用双膦酸盐药物,以减少骨相关事件的发生。局限性及局部浸润性肾癌患者术后尚无标准的可推荐的辅助治疗方案。
Pathological classification of renal cell carcinoma is complex and diverse, but from the clinical drug treatment is divided into two types of clear cell carcinoma and non-clear cell carcinoma. In our country, for the patients with metastatic renal cell carcinoma, sorafenib is the first-line molecular target drug recommended for drug treatment. The other molecular targeted drugs are recommended for clinical trials in China. The cytokine IFN-α or IL- 2 treatment is also a first-line recommendation for clear cell carcinoma of the kidney, while chemotherapy is an option for metastatic non-clear cell type renal cancer. Patients with bone metastases of renal cancer, the proposed application of bisphosphonates to reduce the incidence of bone-related events. Limitations and local invasive renal cell carcinoma patients after surgery there is no standard recommended adjuvant therapy.